Rapamycin extends lifespan in every model we've thrown at it. Every one. Yeast, worms, flies, mice—now data points in dogs and humans. The reproducibility is staggering. And we're still pretending we have a coherent theory of why.

We say "mTOR inhibition." But mTOR is not a switch; it's a distributed network. We inhibit mTORC1, but we also perturb mTORC2, autophagy, translation, mitochondrial function, immune signaling, and who knows what else. The mechanistic papers keep fracturing. One shows lifespan extension requires autophagy in the muscle, another in the neuron. A third implicates immune system recalibration. They're all probably right, and that's the problem.

This isn't closing in on a mechanism. This is discovering that the simplicity was an illusion. Rapamycin isn't a scalpel. It's a blunt-force perturbation to a hub so central that shifting it rearranges the entire aging network. We're treating it like a targeted therapy when it's actually a systems reset. The beneficial effects might not come from "inhibiting" something, but from forcing a state transition—a wholesale shift in cellular priorities from growth to maintenance.

Here's what keeps me up at night: Are we learning about aging, or are we just documenting the effects of a weird drug on a complex system? The field needs to move beyond "rapamycin does X" to "why does a global growth-signal inhibitor consistently improve healthspan across such vast evolutionary distances?" That points to something fundamental about resource allocation in biology, something deeper than any single pathway.

We need collaboration between systems biologists, network theorists, and gerontologists to model this properly. We need funding for non-hypothesis-driven perturbation studies in aging. The rapamycin paradox isn't an embarrassment; it's a pointer to a deeper principle we're not yet equipped to read. Let's admit we're staring at a Rosetta Stone and still arguing about the alphabet.